Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR)

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) are scheduled to reverse split on the morning of Wednesday, October 30th. The 1-10 reverse split was announced on Monday, October 28th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, October 29th.

Kezar Life Sciences Stock Down 1.7 %

Shares of KZR stock traded down $0.01 during trading hours on Monday, reaching $0.77. The company had a trading volume of 1,133,385 shares, compared to its average volume of 738,213. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. Kezar Life Sciences has a twelve month low of $0.52 and a twelve month high of $1.14. The stock’s fifty day simple moving average is $0.68 and its 200 day simple moving average is $0.69. The company has a market capitalization of $56.36 million, a P/E ratio of -0.58 and a beta of 0.21.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, sell-side analysts expect that Kezar Life Sciences will post -1.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th.

Institutional Trading of Kezar Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in KZR. Point72 Asia Singapore Pte. Ltd. bought a new position in Kezar Life Sciences during the 2nd quarter valued at $63,000. Stonepine Capital Management LLC acquired a new position in Kezar Life Sciences during the second quarter worth about $630,000. Mackenzie Financial Corp bought a new stake in Kezar Life Sciences in the second quarter worth about $35,000. Acadian Asset Management LLC lifted its holdings in Kezar Life Sciences by 3.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock valued at $1,112,000 after acquiring an additional 64,356 shares during the last quarter. Finally, Acuitas Investments LLC boosted its position in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after purchasing an additional 295,956 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.